To better handle the growth of technologies intended to reduce the need for animal testing for regulatory decisions, a US Food and Drug Administration Science Board subcommittee suggests the agency establish a central office to oversee so-called new alternative methods (NAMs) in the commissioner’s office.
Animal Testing Alternatives Need Central Office At US FDA, Science Board
Slow adoption of alternatives to animal testing in the current decentralized regulatory framework.
